HERIZON-GEA-01
What it tests: Zanidatamab + chemo ± tislelizumab as first-line in HER2-positive advanced gastroesophageal adenocarcinoma (second interim analysis)
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.